%0 Journal Article
%T Cardiac Remodelling Following Cancer Therapy: A Review.
%A Panpan T
%A Yuchen D
%A Xianyong S
%A Meng L
%A Ruijuan H
%A Ranran D
%A Pengyan Z
%A Mingxi L
%A Rongrong X
%J Cardiovasc Toxicol
%V 22
%N 9
%D 09 2022
%M 35877038
%F 2.755
%R 10.1007/s12012-022-09762-6
%X Cardiac remodelling is characterized by abnormal changes in the function and morphological properties such as diameter, mass, normal diameter of cavities, heart shape, fibrosis, thickening of vessels and heart layers, cardiomyopathy, infiltration of inflammatory cells, and some others. These damages are associated with damage to systolic and diastolic abnormalities, damage to ventricular function, and vascular remodelling, which may lead to heart failure and death. Exposure of the heart to radiation or anti-cancer drugs including chemotherapy drugs such as doxorubicin, receptor tyrosine kinase inhibitors (RTKIs) such as imatinib, and immune checkpoint inhibitors (ICIs) can induce several abnormal changes in the heart structure and function through the induction of inflammation and fibrosis, vascular remodelling, hypertrophy, and some others. This review aims to explain the basic mechanisms behind cardiac remodelling following cancer therapy by different anti-cancer modalities.